Immediate Assessment, Diagnosis, and Initial Management of Acute Coronary Syndrome

ECG‑Based Triage

• The European Society of Cardiology (ESC) recommends that all patients with suspected ACS obtain a 12‑lead ECG within 10 minutes of first medical contact to differentiate STEMI from NSTE‑ACS, directing subsequent therapy. 1
• For STEMI, the ESC advises primary percutaneous coronary intervention (PCI) within 90 minutes (direct presentation) or 120 minutes (transfer); if PCI cannot be achieved in this window, fibrinolytic therapy should be administered. 2
• For NSTE‑ACS, the ESC stresses risk stratification and timing of an invasive strategy based on clinical presentation (e.g., troponin dynamics, ECG changes). 3

Immediate Antiplatelet Therapy

• Aspirin loading 150–300 mg (non‑enteric coated) followed by 75–100 mg daily plus a P2Y12 inhibitor loading dose should be given to every ACS patient. 3
• Ticagrelor 180 mg loading then 90 mg twice daily is the preferred P2Y12 inhibitor for all moderate‑to‑high‑risk patients, irrespective of the initial management strategy. 4
• Prasugrel 60 mg loading then 10 mg daily is indicated for patients proceeding to PCI with known coronary anatomy; it is contraindicated in those with prior stroke/TIA, age ≥ 75 years, or weight < 60 kg. 4
• Clopidogrel 300–600 mg loading then 75 mg daily is reserved for patients unable to receive ticagrelor or prasugrel, or who require concomitant oral anticoagulation. 5

Immediate Anticoagulation

• Fondaparinux is the preferred agent for medically managed ACS patients because it is associated with a lower bleeding risk. 3
• Enoxaparin (low‑molecular‑weight heparin) is an acceptable alternative when fondaparinux is not suitable. 4
• Unfractionated heparin should be used when PCI is planned within a few hours or in the presence of renal dysfunction. 4

Additional Immediate Therapies

• High‑intensity statin therapy (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg) should be started as soon as possible. 6
• Nitroglycerin (sublingual or intravenous) is indicated for ongoing chest pain. 4
• Morphine (intravenous or subcutaneous) may be used for refractory pain, but clinicians should be aware of potential interaction with oral P2Y12 inhibitors. 4
• Supplemental oxygen is recommended only when oxygen saturation < 90 % or the patient is in respiratory distress. 4
• Beta‑blocker (oral) should be administered within 24 hours in the absence of contraindications such as heart failure, hypotension, or bradycardia. 6

Risk Stratification and Timing of Invasive Strategy

Very High‑Risk (Immediate Angiography < 2 h)

• Immediate coronary angiography is indicated for patients with any of the following: hemodynamic instability or cardiogenic shock, recurrent or refractory chest pain, life‑threatening arrhythmias or cardiac arrest, mechanical complications of MI, or acute heart failure with refractory angina/ST‑segment deviation. 2

High‑Risk (Early Angiography < 24 h)

• Angiography within 24 hours is advised for patients showing a rise or fall in cardiac troponin, dynamic ST‑segment or T‑wave changes, or a GRACE score > 140. 2

Intermediate‑Risk (Angiography < 72 h)

• Patients with diabetes mellitus, renal insufficiency (eGFR < 60 mL/min/1.73 m²), left‑ventricular ejection fraction < 40 % or congestive heart failure, a GRACE score 109–140, or a history of prior PCI/CABG should undergo angiography within 72 hours. 3

Cardiac Biomarker Testing

• The ESC recommends high‑sensitivity cardiac troponin (hs‑cTn) measurement on arrival with results available within 60 minutes. 1
• When an hs‑cTn assay is available, a 0‑hour/1‑hour algorithm can be used for rapid rule‑in/rule‑out of MI. 1
• A 0‑hour/2‑hour algorithm is an acceptable alternative when the 1‑hour protocol is not feasible. 1
• If only a conventional troponin assay is available, a 0‑hour/3‑6‑hour protocol should be employed. 3

Reperfusion Strategy for STEMI

• Primary PCI remains the preferred reperfusion method and must be performed within 90 minutes of first medical contact for patients presenting directly to PCI‑capable hospitals, or within 120 minutes for transferred patients. 2
• If PCI cannot be achieved within 120 minutes, fibrinolytic therapy should be administered promptly. 2

Long‑Term Secondary Prevention

Dual Antiplatelet Therapy (DAPT)

• 12 months of aspirin plus a P2Y12 inhibitor is recommended for all ACS survivors; a shorter duration (3–6 months) may be considered in patients at high bleeding risk. 3

Lipid‑Lowering Therapy

• High‑intensity statin therapy should be continued indefinitely. 6

Renin‑Angiotensin‑Aldosterone System (RAAS) Blockade

• ACE inhibitor (or ARB if ACE‑inhibitor intolerant) is indicated for patients with left‑ventricular ejection fraction ≤ 40 %, heart failure, hypertension, or diabetes. 6

Beta‑Blockade

• Beta‑blocker therapy is advised for patients with left‑ventricular ejection fraction ≤ 40 %. 6

Mineralocorticoid Receptor Antagonist

• Eplerenone (preferred) should be added for patients with left‑ventricular ejection fraction ≤ 35 % and heart failure or diabetes, provided there is no significant renal dysfunction or hyperkalaemia. 6

Lifestyle and Rehabilitation

• Smoking cessation, dietary modification, and structured cardiac rehabilitation are essential components of secondary prevention. 6

Critical Pitfalls to Avoid

• Do not postpone reperfusion in STEMI while awaiting biomarker results; the ECG diagnosis alone mandates immediate action. 2
• Avoid administering prasugrel before coronary anatomy is known, as it is contraindicated when coronary artery bypass grafting is required within 5–7 days. 7
• Refrain from routine morphine use in NSTE‑ACS, because it may delay the absorption of oral P2Y12 inhibitors. 4

Acute Coronary Syndrome Management

Introduction to Acute Coronary Syndrome Management

• The American College of Cardiology recommends administering aspirin 150-300 mg (non-enteric coating attack dose) immediately to patients with STEMI, followed by a P2Y12 inhibitor, and activating the catheterization laboratory for primary PCI within 120 minutes 8
• The European Society of Cardiology suggests that for patients with NSTE-ACS at high risk planning for PCI, administer aspirin, a P2Y12 inhibitor, parenteral anticoagulation, and perform coronary angiography within 24 hours (or <2 hours if hemodynamically unstable) 9, 10, 8

Antithrombotic Therapy

• The American Heart Association recommends aspirin 150-300 mg (attack dose), then 75-100 mg daily for antithrombotic therapy in patients with acute coronary syndrome 8, 11
• For patients with NSTE-ACS who are not candidates for PCI, administer complete antithrombotic therapy (aspirin, clopidogrel, anticoagulation) and consider emergency CABG if coronary anatomy is not favorable for PCI 12, 10

Invasive Strategy

• The European Society of Cardiology suggests that after stabilization, consider an ischemia test or coronary angiography to detect obstructive CAD 10
• If coronary anatomy is not favorable for PCI, emergency CABG is recommended 12, 10

Special Considerations

• In cardiogenic shock, perform emergency CABG if anatomy is not favorable for PCI 12, 10
• For mechanical complications (severe acute mitral regurgitation, free wall rupture), consider surgical or catheter-based emergency repair as decided by the Heart Team 12, 10
• Consider using an intra-aortic balloon pump for mechanical complications related to NSTE-ACS; DO NOT use routinely in cardiogenic shock without mechanical complications 12, 10

Monitoring and Evaluation

• Perform continuous cardiac monitoring for at least 24 hours 8
• Measure high-sensitivity troponin on arrival and at 1-2 hours (or 3-6 hours if conventional troponin) 8, 11
• Use echocardiography to assess LV function, valvular function, and exclude complications 12, 10
• Evaluate renal function to adjust medication doses and contrast 9, 10

Evidence‑Based Immediate Management of Acute Coronary Syndrome

Risk Stratification & Timing of Invasive Strategy

• European Society of Cardiology (ESC) 2016 recommendation: All patients with non‑ST‑segment‑elevation ACS (NSTE‑ACS) should undergo formal risk stratification (clinical, ECG, and biomarker assessment) to determine the timing of an invasive strategy. 13
• ESC 2016 laboratory panel: On presentation, obtain serum creatinine, hemoglobin, hematocrit, platelet count, blood glucose, and, if the patient is on anticoagulation, an INR to guide antithrombotic choices. 13
• ESC 2016 indication for ultra‑early angiography (<2 h): Immediate coronary angiography is mandated for NSTE‑ACS patients with recurrent or refractory chest pain despite optimal medical therapy. 13
• ESC 2016 early angiography (within 24 h): Patients showing a rise or fall in cardiac troponin, dynamic ST‑segment or T‑wave changes, or a GRACE score > 140 should receive coronary angiography within 24 hours. 14

Antiplatelet Therapy

• American College of Cardiology/American Heart Association (ACC/AHA) 2012 guidance on prasugrel: A 60 mg loading dose followed by 10 mg daily is recommended for patients proceeding to PCI when coronary anatomy is known; it is contraindicated in those with prior stroke/TIA, age ≥ 75 years, or weight < 60 kg, and must be stopped at least 7 days before planned CABG because of heightened bleeding risk. 14

Glycoprotein IIb/IIIa Inhibitors

• ESC 2016 recommendation: In moderate‑to‑high‑risk NSTE‑ACS patients undergoing PCI, add eptifibatide or tirofiban to aspirin and heparin to further reduce ischemic events. 13

Adjunctive Pharmacologic Considerations

• ESC 2016 morphine caution: Intravenous morphine can delay the absorption of oral P2Y12 inhibitors, potentially compromising antiplatelet efficacy. 13
• ESC 2016 oxygen therapy: Routine supplemental oxygen is not beneficial; it should be administered only when oxygen saturation falls below 90 % or the patient has respiratory distress. 13

Long‑Term Secondary Prevention

• ESC 2016 ACE‑I/ARB use: Initiate an ACE inhibitor (or ARB if ACE‑I intolerant) in ACS survivors with left ventricular ejection fraction ≤ 40 %, heart failure, hypertension, or diabetes to improve morbidity and mortality. 13
• ESC 2016 beta‑blocker use: Prescribe a beta‑blocker for patients with LVEF ≤ 40 % unless contraindicated (e.g., severe heart failure, hypotension, bradycardia). 13
• ESC 2016 lifestyle measures: Strongly advise smoking cessation, dietary modification, and enrollment in cardiac rehabilitation programs as essential components of secondary prevention. 13